SubsidieMeestersWOMED: an innovative intrauterine biodegradable polymer-based drug-delivery platform
Womed aims to revolutionize uterine disorder treatments with innovative local therapies, starting with a drug-free device for fertility and developing solutions for fibroids and endometriosis pain.
Projectdetails
Introduction
Every woman experiences some form of uterine disorder during her lifetime, including excessive bleeding, pelvic pain, and fertility issues, posing an enormous burden for women worldwide. Current treatments have limitations and painful side effects.
Unmet Needs in Women's Health
Fibroids and endometriosis are two of the most relevant unmet needs in women's health. For fibroids, an extremely common condition affecting 51% of women between 35-49, the withdrawal of Esmya, a highly appreciated treatment, has left a gap in effective options. Meanwhile, women with endometriosis (10% of women in reproductive years) suffer incapacitating pain that is poorly managed with systemic analgesics. There is an urgent need for better treatments.
Company Overview
Womed was founded in Montpellier by Gonzague Issenmann, a serial MedTech entrepreneur, to revolutionize the women's health industry by changing the paradigm of uterine disorders treatment.
Product Development
Womed develops safe and effective local intrauterine therapies. Our unique and patented copolymer structure allows for easy insertion, biodegradability, and sustained and controlled local drug delivery.
Current Products
- Womed Leaf: Our first product, a drug-free intrauterine device that prevents adhesions and restores fertility.
Future Developments
Based on Leaf’s design, we are developing a uterine drug delivery platform with:
- Fibroid: A preoperative treatment for fibroids.
- ReLeaf: A non-hormonal treatment to alleviate endometriosis-related pain.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.493.809 |
| Totale projectbegroting | € 3.562.697 |
Tijdlijn
| Startdatum | 1-5-2024 |
| Einddatum | 30-4-2026 |
| Subsidiejaar | 2024 |
Partners & Locaties
Projectpartners
- WOMEDpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Breakthrough dual-action OTC tablet for treatment and prevention of both bacterial and fungal vaginitisGedea aims to commercialize pHyph, an antimicrobial-free pessary for treating and preventing BV and VVC, addressing a significant medical need while avoiding antibiotic resistance. | EIC Accelerator | € 2.499.999 | 2024 | Details |
Restoring a normal life and dignity for women and men suffering from severe Stress Urinary IncontinenceDeveloping UroActive™, a smart artificial urinary sphincter that offers a safe, convenient, and effective solution for severe urinary incontinence, minimizing side effects and restoring patient dignity. | EIC Accelerator | € 2.499.999 | 2023 | Details |
Commercialisation and scale up of a Vaginal Microbiome Screening service with a menstrual tampon collection device and a digital layer to provide diagnosis, disease risk evaluation and aftercare.VMS is a home-based gynaecological test kit that uses tampons for accurate STI and HPV screening, offering comprehensive aftercare and insights into vaginal health. | EIC Accelerator | € 2.499.999 | 2023 | Details |
Hormone-free solution for vaginal atrophyAVeta is a hormone-free medical device providing safe, affordable, and effective self-administered therapy for women suffering from vaginal atrophy, enhancing their quality of life. | EIC Accelerator | € 2.500.000 | 2022 | Details |
Breakthrough dual-action OTC tablet for treatment and prevention of both bacterial and fungal vaginitis
Gedea aims to commercialize pHyph, an antimicrobial-free pessary for treating and preventing BV and VVC, addressing a significant medical need while avoiding antibiotic resistance.
Restoring a normal life and dignity for women and men suffering from severe Stress Urinary Incontinence
Developing UroActive™, a smart artificial urinary sphincter that offers a safe, convenient, and effective solution for severe urinary incontinence, minimizing side effects and restoring patient dignity.
Commercialisation and scale up of a Vaginal Microbiome Screening service with a menstrual tampon collection device and a digital layer to provide diagnosis, disease risk evaluation and aftercare.
VMS is a home-based gynaecological test kit that uses tampons for accurate STI and HPV screening, offering comprehensive aftercare and insights into vaginal health.
Hormone-free solution for vaginal atrophy
AVeta is a hormone-free medical device providing safe, affordable, and effective self-administered therapy for women suffering from vaginal atrophy, enhancing their quality of life.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Menstrual blood multiomics analysis to better diagnose, understand and treat endometriosisThe MensEndoDiag project seeks to identify diagnostic and prognostic biomarkers for endometriosis using menstrual fluid, while exploring new therapeutic approaches to improve patient outcomes. | ERC Starting... | € 1.479.399 | 2023 | Details |
Personalised Adaptive MedicineThe PERAMEDIC project aims to develop a desktop-sized system for personalized polypill formulation using 3D printing and precise dosing to enhance treatment outcomes and patient adherence. | EIC Pathfinder | € 1.726.876 | 2024 | Details |
Chemogels voor de behandeling van uitgezaaide buikvlieskankerUPyTher ontwikkelt innovatieve hydrogels voor lokale chemotherapie bij buikvlieskanker om de effectiviteit van behandelingen te verbeteren. | Mkb-innovati... | € 20.000 | 2023 | Details |
An injectable and programmable drug-eluting embolic deviceThis project develops a novel biodegradable drug delivery platform for liver cancer treatment, utilizing a two-step method to enhance drug perfusion and reduce adverse effects before vessel blockage. | ERC Proof of... | € 150.000 | 2023 | Details |
A completely biological and human tissue-engineered sling produced from Cell-Assembled extracellular Matrix (CAM) in vitro for the treatment of Stress Urinary Incontinence (SUI)This project aims to develop and validate soft, biologically-based CAM slings for treating Stress Urinary Incontinence, addressing complications of synthetic slings through in vivo testing in sheep. | ERC Proof of... | € 150.000 | 2025 | Details |
Menstrual blood multiomics analysis to better diagnose, understand and treat endometriosis
The MensEndoDiag project seeks to identify diagnostic and prognostic biomarkers for endometriosis using menstrual fluid, while exploring new therapeutic approaches to improve patient outcomes.
Personalised Adaptive Medicine
The PERAMEDIC project aims to develop a desktop-sized system for personalized polypill formulation using 3D printing and precise dosing to enhance treatment outcomes and patient adherence.
Chemogels voor de behandeling van uitgezaaide buikvlieskanker
UPyTher ontwikkelt innovatieve hydrogels voor lokale chemotherapie bij buikvlieskanker om de effectiviteit van behandelingen te verbeteren.
An injectable and programmable drug-eluting embolic device
This project develops a novel biodegradable drug delivery platform for liver cancer treatment, utilizing a two-step method to enhance drug perfusion and reduce adverse effects before vessel blockage.
A completely biological and human tissue-engineered sling produced from Cell-Assembled extracellular Matrix (CAM) in vitro for the treatment of Stress Urinary Incontinence (SUI)
This project aims to develop and validate soft, biologically-based CAM slings for treating Stress Urinary Incontinence, addressing complications of synthetic slings through in vivo testing in sheep.